Autolus Therapeutics Plc Revenue Growth Rates (AUTL), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Autolus Therapeutics Plc  (NASDAQ: AUTL)
 

AUTL's Revenue Growth by Quarter and Year

Autolus Therapeutics Plc's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/AUTL/growth
https://api.csimarket.com/api/v1/companies/AUTL/fundamentals
https://api.csimarket.com/api/v1/companies/AUTL/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
AUTL Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 41.24
2nd Quarter June 45.69
1st Quarter March 26.22
FY 113.15

AUTLs Annual Revenue
Autolus Therapeutics Plc's Revenue in the fiscal year 2025 $ 75.39 millions
Autolus Therapeutics Plc's Revenue in the fiscal year 2024 $ 10.12 millions
Autolus Therapeutics Plc's Revenue in the fiscal year 2023 $ 1.70 millions
Autolus Therapeutics Plc's Revenue in the fiscal year 2022 $ 0.17 millions
Autolus Therapeutics Plc's Revenue in the fiscal year 2021 $ 0.82 millions




AUTL Revenue third quarter 2026 Y/Y Growth Comment
Autolus Therapeutics Plc achieved in the third quarter 2026, above Company average Revenue rise of 94.61% year on year, to $ 41.24 millions.

Looking into third quarter 2026 results within Biotechnology & Pharmaceuticals industry 17 other companies have achieved higher Revenue growth. While Autolus Therapeutics Plc' s Revenue jump of 94.61% ranks overall at the positon no. 352 in the third quarter 2026.


AUTL Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 94.61 %
2nd Quarter June 118.4 %
1st Quarter March 191.98 %
FY   -

Financial Statements
Autolus Therapeutics Plc's third quarter 2026 Revenue $ 41.24 millions AUTL's Income Statement
Autolus Therapeutics Plc's third quarter 2025 Revenue $ 21.19 millions Quarterly AUTL's Income Statement


AUTL Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -9.74 %
2nd Quarter June 74.26 %
1st Quarter March 7.95 %
FY (Year on Year)   -


Back to AUTL Growth rate Comparisons >> Back to AUTL Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #18
Healthcare Sector #94
Overall #352

Revenue Y/Y Growth Statistics
High Average Low
-44.13 % -57.63 % -79.83 %
(Dec 31 2021)   (Dec 31 2022)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #18
Healthcare Sector #94
Overall #352
Revenue Y/Y Growth Statistics
High Average Low
-44.13 % -57.63 % -79.83 %
(Dec 31 2021)   (Dec 31 2022)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Autolus Therapeutics Plc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
30872.41 % 1425.02 % -100 %
(Mar 31 2025)  


AUTL's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Autolus Therapeutics Plc disclosed drop in Revenue from the second quarter by -9.74% to $ 41.24 millions, from $ 45.69 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2026 Revenue, this plainly could not be substantial to rescue Biotechnology & Pharmaceuticals's company achievement, Most analysts pointed out.

Within Biotechnology & Pharmaceuticals industry 7 other companies have achieved higher Revenue quarter on quarter growth. While Autolus Therapeutics Plc's Revenue growth quarter on quarter, overall rank is 164.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #8
Healthcare Sector #49
Overall #164
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #8
Healthcare Sector #49
Overall #164
Revenue Q/Q Growth Statistics
High Average Low
30872.41 % 1425.02 % -100 %
(Mar 31 2025)  


AUTL's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Autolus Therapeutics Plc disclosed drop in Revenue from the second quarter by -9.74% to $ 41.24 millions, from $ 45.69 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2026 Revenue, this plainly could not be substantial to rescue Biotechnology & Pharmaceuticals's company achievement, Most analysts pointed out.

Within Biotechnology & Pharmaceuticals industry 7 other companies have achieved higher Revenue quarter on quarter growth. While Autolus Therapeutics Plc's Revenue growth quarter on quarter, overall rank is 164.


Autolus Therapeutics Plc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 137.43
Y / Y Revenue Growth (TTM) 168.8 %
Year on Year Revenue Growth Overall Ranking #
Seqeuential Revenue Change (TTM) 17.07 %
Seq. Revenue Growth (TTM) Overall Ranking # 352


Cumulative Revenue growth Comment
With 168.8% annual Revenue growth, Autolus Therapeutics Plc would report a record annual Revenue surge if the fiscal year would end on Sep 30 2026.

Within the Healthcare sector 31 other companies have achieved higher trailing twelve month Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 5
Healthcare Sector # 32
Overall # 105

Revenue TTM Y/Y Growth Statistics
High Average Low
168.8 %
 -19.89 %
-79.83 %
(Sep 30 2026)  


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 18
Sector # 94
S&P 500 # 352
Cumulative Revenue growth Comment
With 168.8% annual Revenue growth, Autolus Therapeutics Plc would report a record annual Revenue surge if the fiscal year would end on Sep 30 2026.

Within the Healthcare sector 31 other companies have achieved higher trailing twelve month Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 5
Healthcare Sector # 32
Overall # 105

Revenue TTM Y/Y Growth Statistics
High Average Low
168.8 %
-19.89 %
-79.83 %
(Sep 30 2026)  


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 18
Sector # 94
S&P 500 # 352




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
AUTL's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue surge for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Eton Pharmaceuticals Inc 165.04%$ 165.042 millions
Sera Prognostics Inc 162.50%$ 162.500 millions
Volitionrx Limited157.28%$ 157.283 millions
Neuraxis Inc 149.92%$ 149.922 millions
Pluri Inc 140.19%$ 140.190 millions
Camp4 Therapeutics Corporation138.87%$ 138.868 millions
Sonida Senior Living Inc 114.40%$ 114.402 millions
Verastem Inc 113.59%$ 113.592 millions
Hyperfine Inc 109.27%$ 109.270 millions
Pelthos Therapeutics Inc 107.87%$ 107.872 millions
Co diagnostics Inc 94.58%$ 94.580 millions
Autolus Therapeutics Plc94.57%$ 94.574 millions
Qt Imaging Holdings Inc exact Name Of Registrant As Specified In Its Charter _______________________93.02%$ 93.022 millions
Keros Therapeutics Inc 88.77%$ 88.766 millions
Profound Medical Corp 85.86%$ 85.857 millions
Vivosim Labs Inc 82.14%$ 82.143 millions
Syndax Pharmaceuticals Inc 81.59%$ 81.592 millions
Nuo Therapeutics Inc 80.81%$ 80.809 millions
Iovance Biotherapeutics inc 80.07%$ 80.074 millions
Rhythm Pharmaceuticals Inc 79.59%$ 79.594 millions
Omniab Inc 78.34%$ 78.339 millions
Aclarion Inc 78.09%$ 78.086 millions
Personalis Inc 76.59%$ 76.585 millions
Delcath Systems Inc 76.05%$ 76.047 millions
Mobia Medical Inc 73.28%$ 73.280 millions
Wave Life Sciences Ltd 72.95%$ 72.950 millions
Igc Pharma Inc 71.73%$ 71.728 millions
Phathom Pharmaceuticals Inc 71.14%$ 71.142 millions
Ptc Therapeutics inc 69.57%$ 69.571 millions
Seres Therapeutics Inc 68.95%$ 68.946 millions


About Autolus Therapeutics Plc Revenue Growth Rates (AUTL), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Autolus Therapeutics Plc (CIK 1730463).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001730463-26-000148
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Autolus Therapeutics Plc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.